Dataset Information
Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial.
Ontology highlight
ABSTRACT:
SUBMITTER: Kiritsi D
PROVIDER: S-EPMC11558043 | biostudies-literature | 2024 Nov
REPOSITORIES: biostudies-literature
Publications
Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial.
EClinicalMedicine 20241030
<h4>Background</h4>Recessive dystrophic epidermolysis bullosa (RDEB) is a skin fragility disorder characterised by life-long mechanically induced skin blistering, fibrosis-driven pseudosyndactyly, and multi-organ involvement. Preclinical studies have suggested mitigated progression by angiotensin II type I receptor blockade through losartan. We aimed to determine the safety and tolerability of systemic losartan treatment among children with RDEB, and to obtain initial data on its clinical benefi ...[more]
